{"filing":{"accession_number":"0001437749-26-025474","cik":"0001659617","ticker":"MBRX","company_name":"Moleculin Biotech, Inc.","form":"8-K","filing_date":"2026-08-03","report_date":"2026-07-31","primary_document":"mbrx20260803_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1659617/000143774926025474/mbrx20260803_8k.htm"},"events":[{"id":23243,"run_id":21014,"accession_number":"0001437749-26-025474","anchor_item_number":"1.01","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"Moleculin Biotech entered into a placement agency agreement with Roth Capital Partners for a public offering of 12.4 million shares of common stock (or pre-funded warrants) and 37.1 million common stock purchase warrants at $0.75 per share, raising approximately $9.3 million gross proceeds. This is a dilutive equity issuance that materially increases the share count and dilutes existing shareholders, with the company restricting future issuances for 45–180 days post-closing and insiders subject to 60-day lock-ups.","company_name":"Moleculin Biotech, Inc.","ticker":"MBRX","filing_date":"2026-08-03","form":"8-K","submitted_at":null,"items":[{"id":23425,"accession_number":"0001437749-26-025474","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Moleculin Biotech entered into a placement agency agreement with Roth Capital Partners for a public offering of 12.4 million shares of common stock (or pre-funded warrants) and 37.1 million common stock purchase warrants at $0.75 per share, raising approximately $9.3 million gross proceeds. This is a dilutive equity issuance that materially increases the share count and dilutes existing shareholders, with the company restricting future issuances for 45–180 days post-closing and insiders subject to 60-day lock-ups.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-04T00:50:46.989866+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":23425,"accession_number":"0001437749-26-025474","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Moleculin Biotech entered into a placement agency agreement with Roth Capital Partners for a public offering of 12.4 million shares of common stock (or pre-funded warrants) and 37.1 million common stock purchase warrants at $0.75 per share, raising approximately $9.3 million gross proceeds. This is a dilutive equity issuance that materially increases the share count and dilutes existing shareholders, with the company restricting future issuances for 45–180 days post-closing and insiders subject to 60-day lock-ups.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-04T00:50:46.989866+00:00","company_name":"Moleculin Biotech, Inc.","ticker":"MBRX","filing_date":"2026-08-03"}]}